Moderna Inc

NASDAQ:MRNA  
307.05
+5.56 (+1.84%)
5:02:53 PM EDT: $304.38 -2.67 (-0.87%)
Products

Moderna Announces Positive Data From Phase 2 Study Of mRNA VEGF-A Therapeutic

Published: 11/15/2021 14:44 GMT
Moderna Inc (MRNA) - Moderna Announces Positive Data From Phase 2 Study of Mrna Vegf-a Therapeutic in Patients Undergoing Coronary Artery Bypass Grafting Surgery.
Moderna Inc - Results Support Further Investigation of Azd8601 for Efficacy and Safety in Future Larger Studies.
Moderna Inc - Phase 2a Study Met Primary Endpoint of Safety and Tolerability.
Moderna Inc - Numerical Trends Observed in Endpoints in Heart Failure Efficacy Domains Compared With Placebo.
Moderna Inc - Phase 2 Study Met Primary Endpoint of Safety and Tolerability of Azd8601.
Moderna Inc - All Seven Patients Treated With Azd8601 Had Nt-probnp Levels Below Heart Failure (hf) Limit at 6 Months.